ArticleCytometry. Part B, Clinical cytometry2016
Saturation monitoring of VX15/2503, a novel semaphorin 4D-specific antibody, in clinical trials.
Article in Cytometry. Part B, Clinical cytometry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Association between prognosis and SEMA4D/Plexin-B1 expression in various malignancies: A meta-analysis.Medicine · 2019Pooled it
- A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614).Pediatric blood & cancer · 2024Trial
- SEMA4D/PlexinB1 promotes AML progression via activation of PI3K/Akt signaling.Journal of translational medicine · 2022Article
- Anti-Semaphorin 4D Rescues Motor, Cognitive, and Respiratory Phenotypes in a Rett Syndrome Mouse Model.International journal of molecular sciences · 2021Article
- Semaphorins in Angiogenesis and Autoimmune Diseases: Therapeutic Targets?Frontiers in immunology · 2020Review
- Semaphorins and Their Receptors in Hematological Malignancies.Frontiers in oncology · 2019Review
- Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial.Neurology(R) neuroimmunology & neuroinflammation · 2017Article
- Intact CD100-CD72 Interaction Necessary for TCR-Induced T Cell Proliferation.Frontiers in immunology · 2017Article
- Current drug design to target the Semaphorin/Neuropilin/Plexin complexes.Cell adhesion & migration · 2016Review
- Transmembrane semaphorins: Multimodal signaling cues in development and cancer.Cell adhesion & migration · 2016Review
- Saturation monitoring of VX15/2503, a novel semaphorin 4D-specific antibody, in clinical trials.Cytometry. Part B, Clinical cytometry · 2016Article
- The role of semaphorin 4D in tumor development and angiogenesis in human breast cancer.OncoTargets and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReceptor occupancy, or saturation, assays are often utilized in preclinical and clinical development programs to evaluate the binding of a biologic to a cellular target. These assays provide critical information regarding the dose of drug required to "saturate" the target as well as important pharmacodymamic (PD) data. A flow cytometric method was developed to measure the degree of Semaphorin 4D (SEMA4D; CD100) saturation by VX15/2303, an investigational monoclonal antibody specific for SEMA4D.
methodsThe assay detects VX15/2503, a human IgG4 specific for SEMA4D, with an IgG4 -specific monoclonal antibody.
resultsData generated allowed assessment of two related SEMA4D-specific pharmacodynamic (PD) markers: (1) The measurement of cellular SEMA4D (cSEMA4D) saturation by VX15/2503, and (2) the cell membrane expression levels of cSEMA4D.
conclusionsThis assay specifically and reproducibly measured cSEMA4D saturation and expression levels. Evaluation of the SEMA4D-specific PD markers were critical in determining the clinical saturation threshold of cSEMA4D by VX15/2503.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.